IL1B and idiopathic interstitial pneumonia: Interestingly, both approved antifibrotic agents for the treatment of IPF (nintedanib and pirfenidone) have been shown to reduce IL-1ß expression in lung tissues (53, 54), which might be a mechanism for the reduced risk of acute exacerbation in patients receiving antifibrotic treatment (55, 56).